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Abstract: Multidrug resistance (MDR) is a major obstacle to cancer chemotherapy. We evaluated 
the effect of daunorubicin (DNR)-loaded magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) on 
K562-n/VCR cells in vivo. K562-n and its MDR counterpart K562-n/VCR cell were inoculated 
into nude mice subcutaneously. The mice were randomly divided into four groups: group A 
received normal saline, group B received DNR, group C received MNPs-Fe3O4, and group D 
received DNR-loaded MNPs-Fe3O4. For K562-n/VCR tumor, the weight was markedly lower 
in group D than that in groups A, B, and C. The transcriptions of Mdr-1 and Bcl-2 gene were 
significantly lower in group D than those in groups A, B, and C. The expression of Bcl-2 was 
lower in group D than those in groups A, B, and C, but there was no difference in the expression 
of P-glycoprotein. The transcriptions and expressions of Bax and caspase-3 in group D were 
increased significantly when compared with groups A, B, and C. In conclusion, DNR-loaded 
MNPs-Fe3O4 can overcome MDR in vivo.
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Introduction
The development of new cytotoxic drugs and treatment strategies has resulted in 
improved response rates for patients with hematological malignancies. However, 
multidrug resistance (MDR) is the primary cause for almost 90% of cancer treat-
ment failures.1,2 Cancer cells are becoming resistant to the cytotoxic effects of a wide 
range of structurally and mechanistically unrelated anticancer drugs. It has been 
proved that various molecular mechanisms,3 including the activation of detoxifying 
systems of the glutathione-S-transferase gene, DNA repair, and alteration in drug-
induced apoptosis of genes in the Bcl-2 pathway, contribute to the complex story of 
cancer drug resistance. However, the most commonly encountered effect of MDR in 
the laboratory is the decreased intracellular drug accumulation caused by enhanced 
drug efflux from tumor cells.4 This is related to the overexpression of a family of 
energy-dependent transporters,1 known as ATP-binding cassette (ABC) transporters 
such as P-glycoprotein (P-gp) and MDR-associated protein.2,5 Among these ABC 
transporters, P-gp confers cancer cells the strongest resistance to the widest variety 
of compounds. P-gp, a 170-kDa membrane-associated glycoprotein, transports a 
broad class of hydrophobic cytotoxic drugs that are central to most chemotherapeutic 
regimens from cell cytoplasm to outside the plasma membrane.6 Despite the wealth 
of information collected about the biochemistry and substrate specificity of P-gp and 
other types of ABC transporters, translation of this knowledge from the bench to the 
bedside has proved to be unexpectedly difficult. Because cytotoxic drugs typically International Journal of Nanomedicine 2009:4 202
Chen et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
carry numerous dose-limiting normal tissue side effects,7 it is 
generally impractical to overcome this form of drug resistance 
simply by increasing the drug dose. Extensive efforts have 
been made to design P-gp modulators (chemosensitizers). 
Unfortunately, modulation of P-gp activity by current 
chemosensitizers to inhibit ABC transporters is limited for 
several reasons, such as low efficiency, strong adverse effects, 
and pharmacokinetic interactions that limit anticancer drug 
clearance and metabolism.2
Nanotechnology is no stranger to oncology.8 A wide 
variety of nanovectors have been used for the delivery of 
anticancer drugs to overcome drug resistance as well as to 
improve the effectiveness and safety of cancer chemotherapy,9 
such as the use of drug-loaded liposomes,10–12 stealth 
liposomes,13,14 polymeric nanospheres with equivalent 
stealth properties, polymeric nanocapsules,15,16 and solid 
lipid nanoparticles.17 The major advantages sought by the 
use of nanovectors over simple drugs are as follow: the 
specific delivery of large amounts of therapeutic agents 
using biorecognition targets;18 protection of the drug from 
premature degradation and interaction with the biological 
environment; enhanced absorption of the drugs into a 
selected tissue through enhanced permeability and retention 
(EPR) effect; controlling the pharmacokinetic and drug 
tissue distribution profile; and improvement of intracellular 
penetration,19 which ameliorates the therapeutic index.
In our previous research, we have developed tetraheptyl-
ammonium-capped MNPs-Fe3O4,20,21 which could facilitate 
the drug accumulation of daunorubicin (DNR) inside MDR 
leukemia K562/A02 cells and enhance the response of DNR 
in MDR leukemia K562/A02 cells in vitro.21 It has been 
demonstrated that DNR polymerized with MNPs-Fe3O4 have 
shown more chemosensitizing activities than those of DNR 
alone. The cytotoxicity test in vitro revealed that MNPs-Fe3O4 
exhibit excellent biocompatibility.22 Furthermore, no 
carcinogenic effects have been observed for MNPs-Fe3O4.23 
Its effect on MDR leukemic cells in vivo remains unknown. 
In this work, we demonstrate that DNR-loaded MNPs-Fe3O4 
are able to reverse MDR leukemic K562-n/VCR cells in vivo 
by inducing apoptosis. However, DNR-loaded MNPs-Fe3O4 
fails to enhance cytotoxicity response in sensitive leukemic 
K562-n cells in vivo.
Materials and methods
Preparation of DNR-loaded MNPs-Fe3O4
MNPs-Fe3O4 were produced by electrochemical deposition 
under oxidizing conditions in a 0.1 mol/L tetraheptylam-
monium 2-propanol solution, where the magnetization and 
the size of MNPs-Fe3O4 was found to be 25.6 × 10−3 emu/mg 
and 30 nm, respectively. The deposited clusters were capped 
with tetraheptylammonium, which acts as a stabilizer of the 
colloidal nanocrystallites.20 Before being applied in this 
experiment, the magnetized nanoparticles of Fe3O4 were 
well distributed in 0.9% NaCl solution by using ultrasound 
treatment in order to obtain colloidal suspension of 
MNPs-Fe3O4. 0.2 g/L DNR (Sigma Aldrich, St. Louis, MO, 
USA) conjugated with 0.116 g/L MNPs-Fe3O4 were prepared 
by mechanical absorption polymerization as previously 
reported.24,25
Cell lines and cell culture
K562-n, a cell strain with high tumorigenicity in nude mice, 
was derived from K562 cells, which were cloned from 
human chronic myelogenous leukemia by repeated passage 
in nude mice and in culture alternatively.26 MDR leukemia 
cell K562-n/VCR, which expresses MDR gene (mdr-1), 
was established by a long-term, intermittent, low-dose, and 
gradually escalated vincristine (VCR) added into the culture 
medium. K562-n/VCR has been proved to be resistant to 
some extent to many cytotoxins including VCR, DNR, and 
has high tumorigenicity in nude mice.27 It has been proved that 
K562-n/VCR cells in the xenograft model had a comparatively 
stable MDR phenotype to the corresponding cells.28 
K562-n and K562-n/VCR cells (gifted from the department 
of hematology, Shanghai Hospital, Second Military Medical 
University, Shanghai, China) were maintained in RPMI 
1640 medium (Gibco, Carlsbad, CA, USA) with 10% fetal 
bovine serum (Sijiqing, Hang Zhou, China), penicillin G 
(100 IU/mL), and streptomycin (100 µg/mL) at 37 °C in a 
humidified 5% CO2 atmosphere. 0.64 µg/ml VCR was added 
regularly in K562-n/VCR culture medium to maintain drug 
resistance. K562-n/VCR cells were incubated in VCR-free 
medium for over two weeks before the planned experiment.
Animals and establishment of the 
xenograft leukemia model in nude mice
Female BALB/c-nu/nu mice were purchased from Beijing 
National Center for Laboratory Animals, the Chinese 
Academy of Medical Sciences, and were four weeks old at 
the beginning of our experiments. They were maintained in 
specific pathogen-free (SPF) facilities in our college and fed 
with irradiated chow. The two subclones of cells, K562-n 
and K562-n/VCR, were inoculated subcutaneously into each 
side of the back of athymic nude mice (5 × 106 cells/each) 
simultaneously, resulting in the formation of two tumors 
per mouse. The mice were assigned randomly to five groups International Journal of Nanomedicine 2009:4 203
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after inoculation for 10 days when both tumors formed. 
Mice in the control group were treated with normal saline 
0.2 ml (group A). Nude mice in group B were treated 
with MNPs-Fe3O4 (0.58 mg/kg). Group C were treated with 
DNR (1 mg/kg). Group D were treated with MNPs-Fe3O4 
(0.58 mg/kg) loaded with DNR (1 mg/kg) every other day 
for 20 days by vena caudalis injection, respectively.28
Tumor assessment
After the planned treatment all animals were killed with 
ether anesthesia. Tumors were isolated for weight detection 
and then for quantitative real-time reverse transcription–
polymerase chain reaction and western blotting.
Quantitative real-time reverse 
transcription–polymerase chain reaction
A total RNA of K562-n/VCR tumors from all groups and 
K562-n tumor of group A were isolated by using Trizol reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. One microgram of total 
RNA was used to generate cDNA by using SuperScript II 
Reverse Transcriptase (Invitrogen Life Technologies). PCR 
primers were designed to amplify products within target and 
control sequences (primer sequences for Mdr-1 (427 bp) 
forward, 5-TGGT TTGATGTGCACGATGTTGGG-3    and 
reverse, 5-AGATCAGCAGGAAAGCAGCACCTA-3   ; Bcl-2 
(452bp) forward, 5-GGGAGAACAGGGTACGATAA-3    and 
reverse, 5 -CCACCGAACTCAAAGAAGG-3   ; Bax (114bp) 
forward, 5   -TTTTGCTTCAGGGTTTCATC-3    and reverse, 
5 -GACACTCGCTCAGCTTCTTG-3   ; caspase-3 (445 bp) 
forward, 5-CACAATAGCACCCATCCG-3  and reverse, 
5 -GGGACATCAGTCGCTTCA-3 ; GAPDH (205bp) 
forward, 5 -CGGATTTGGTCGTATTG-3  and reverse, 
5 -GAAGATGGTGATGGGATT-3   ). Quantitative PCR 
was performed by monitoring in real-time the increase in 
fluorescence of SYBR green I dye (Takara, Shiga, Japan) 
with Rotor-Gene 3000 (Corbett Research, Sydney, Australia). 
Each experiment was undertaken in triplicate. The relative 
gene copy number was calculated by the concentration-CT 
standard curve method and normalized using the average 
expression of GAPDH.
Western blot analysis
Western blotting was used for the detection of P-gp. After 
treatment for 20 days, 0.1 g K562-n/VCR tumor tissue 
was collected from each mouse and homogenized for P-gp 
detection, tumor tissue from K562n is used as negative control. 
Tissues were extracted with 1 g/L Triton X-100 and protein 
concentration was determined with a Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Hercules, CA, USA) and standardized 
with bovineserum albumin. A 50 µg sample of protein was 
separated on electrophorased SDS-PAGE and electroblotted 
onto PVDF membrane (BioRad Laboratories). The membrane 
was blocked with buffer containing 10% fat free dry milk. 
Mouse anti-Bcl-2 antibody (1:500), mouse anti-Bax antibody 
(1:500), mouse anti-Caspase-3 antibody (1:500), mouse anti-
P-gp antibody (1:500) and mouse anti-β-actin antibody (1:500) 
were used respectively as the primary antibody. Horseradish 
peroxidase-conjugated anti-rabbit antibody (1:1000) was 
the secondary antibody. The band was detected by using an 
enhanced chemiluminescence (ECL) detection system.
statistical analysis
For tumor diameter assessment and pathological examina-
tions, experiments were repeated at least three times and 
evaluated by two independent researchers when indicated. 
Reported values represent the means ± SD. The significance 
of differences between experimental variables was deter-
mined using parametric Student’s t-test.
Results
DNR-loaded MNPs-Fe3O4 could greatly suppress the growth 
of K562n/VCR tumor, but failed to further inhibit the pro-
liferation of sensitive K562-n tumor in vivo.
All models of nude mice with transplanted leukemic 
K562-n cell and its MDR counterpart K562n/VCR were 
established after subcutaneous injection for 10 days, with 
an average volume of 100 mm3. The rate of subcutaneous 
tumor formation was 100%. For MDR-bearing K562-n/VCR 
tumors, there was no significant difference in the average tumor 
weight between groups A and B, the average tumor volume 
of group C seemed smaller but without statistic difference. 
The average tumor weight was less in group D than that in 
groups A, B, and C (P  0.05) (Figure 1A). For sensitive 
K562-n tumors, there was no significant difference in the 
average tumor weight between groups A and B. The average 
tumor weight was less in groups C and D than that in groups 
A and B (P  0.05). But the average tumor weight showed 
no difference in groups C and D (Figure 1B).
Transcription of Mdr-1, Bcl-2, Bax,  
and caspase-3 in K562-n/VCR tumor  
by RT-PCR
The transcription of Mdr-1 and Bcl-2 gene was significantly lower 
in group D than those in groups A, B, and C (group D vs groups 
A, B, or C; P  0.05). The transcription of Bax and caspase-3 International Journal of Nanomedicine 2009:4 204
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increased more significantly in group D than in groups A, B, and C 
(group D vs groups A, B, or C; P  0.05) (Figure 2).
expression of P-gp, Bcl-2, Bax,  
and caspase-3 proteins in K562-n/VCR 
tumor by western blot
Based on computer-assisted image analysis, it appeared that 
there was no difference in the P-gp expression among the four 
groups (Figure 3). The expression of Bcl-2 was significantly 
lower in group D than in groups A, B, and C (group D vs groups 
A, B, or C; P  0.05). The expression of Bax and caspase-3 
increased more significantly in group D than in groups A, B, 
and C (group D vs groups A, B, or C; P  0.05) (Figure 4).
Discussion
In the present study, DNR-loaded MNPs-Fe3O4 could 
selectively inhibit the growth of MDR leukemic K562-n/VCR 
cells that transplanted in nude mice when compared 
with DNR alone according to the average tumor weight 
(P  0.05), while MNPs-Fe3O4 didn’t show any antitumor 
activity without DNR.
Many chemotherapeutic agents target intracellular 
organelles or molecules to achieve their anticancer activities.29 
Effective chemotherapy thus requires an effectively high level 
of drug molecules to accumulate within the cancer cells. In 
addition, the effectiveness of chemotherapy is also correlated 
with drug exposure time.30 In P-gp overexpressing cells, it 
becomes a difficult task to maintain a high intracellular drug 
level for a reasonable length of time. Experimental studies 
have shown that the main antitumor effect of anthracyclines 
is correlated to the induction of apoptotic cells.31 Escape 
from apoptotic signals often accompanies MDR and tumor 
progression.32,33 In general, apoptosis may occur through 
specific apoptosis signaling pathways such as death receptors 
and mitochondria. However, the mitochondrial pathway plays 
a crucial role in anthracycline-related apoptosis,34 which is 
regulated by the Bcl-2 protein family.35 Bcl-2 family pro-
teins consist of antiapoptotic and pro-apoptotic members.36 
Previous reports have also documented that the ratio of 
antiapoptotic Bcl-2 to proapoptotic Bax protein determined, 
at least in part, the susceptibility of cells to a death signal,37 
and are used as a predictive marker for therapeutic response 
to radiotherapy.38 It is well known that caspase-3 plays the 
central role in the initiation of apoptosis.39 Our study showed 
that DNR-loaded MNPs-Fe3O4 could decrease the expression 
of Bcl-2 and increase the expression of Bax and caspase-3 in 
K562-n/VCR tumors (P  0.05), indicating that this therapy 
can overturn poor response and induce apoptosis of MDR 
K562-n/VCR cells to anticancer drugs in vivo. Our outcomes 
clearly indicate that a MNPs-Fe3O4 drug delivery system 
can facilitate DNR accumulation in MDR cells and enhance 
apoptosis in MDR cells.
It has been reported that DNR can interact with DNA in 
the presence of Fe (III) ions which hampers the recognition of 
DNA by transcription factors and then inhibits transcription.40 
We also found that DNR-loaded MNPs-Fe3O4 could down-
regulate the transcription of mdr-1 gene. The downregulation 
of the transcription of mdr-1 gene may attribute to the 
relatively high DNR concentration in K562-n/VCR, since 
MNPs-Fe3O4 alone is not able to inhibit the mdr-1 gene 
transcription. On the contrary, there is no difference in the 
quantity of P-gp on K562-n/VCR tumors among the four 
groups. Therefore functionalized MNPs-Fe3O4 can enhance 
DNR accumulation inside MDR cells without interfering 
with the quantity of P-gp, a mechanism which differs from 
many types of P-gp modulators such as tetrandrine, PC833, 
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and so on.41 Quantity or content, but not function, of P-gp can 
be detected by western blot. Studies have shown that some 
of the lipids and surfactants used in detergent-based formu-
lations including Pluronic block copolymers and solid lipid 
nanoparticles possess intrinsic P-gp inhibitory activities.42 
Looking at structural features, Pluronic block copolymers, 
solid lipid nanoparticles, and tetraheptylammonium-capped 
MNPs-Fe3O4 are similar in having hydrophobic segments. 
The literature suggests that nonionic surfactants may inhibit 
drug efflux transport through increased membrane fluidiza-
tion, which induces changes in the conformation of P-gp and 
ATPase activity.43 It is reasonable to infer from enhanced 
DNR accumulation inside the MDR cells that hydrophobic 
tetraheptyl segments capped outside MNPs-Fe3O4 can 
incorporate DNR in the lipid membrane and induce changes 
in membrane structure. The interrelationship between the 
membrane fluidization and the suppression of P-gp ATPase 
activity can be better understood in view of the current 
picture of P-gp structure describing P-gp that contains two 
transmembrane domains (TMDs) and two nucleotide ATP-
binding domains (NBDs).2 Structures of P-gp protein suggest 
that the two NBDs form a common binding site where the 
energy of ATP is harvested to promote efflux through a pore 
that is delineated by transmembrane helices.44 Proper interac-
tion of these two ATP-binding sites is crucial for the proper 
functioning of P-gp.43 Therefore, the structural perturba-
tions in the lipid membranes induced by MNPs-Fe3O4 may 
decrease the affinity of ATP to its binding site and interfere 
with the ATPase activity. Not only have MNPs-Fe3O4 the 
ability to block P-gp function, but they also have the poten-
tial for aggregation and drug capsulation.42,45 Nanoparticles 
loaded with anticancer drugs could readily approach the 
cell membrane, leading to drug concentrations at the cell 
surface higher than those obtained with the same amount of 
free drug solution, which leads in turn to higher intracellular 
drug concentrations.46,47 It has been reported that it is more 
difficult for P-gp to remove the drug molecules from the 
cells when these molecules are associated with nanoparticles. 
DNR-loaded MNPs-Fe3O4 complexes are likely to be too 
large to be handled by P-gp and are consequently “trapped” 
within the cancer cells once they gain entrance into the 
targeted cells.42 This is another possible mechanism respon-
sible for enhanced cellular drug retention. These mechanisms 
may be the reason that MNPs-Fe3O4, which has no cytotox-
icity to cells, is able to reverse MDR. Another important 
observation of the present work is that DNR-loaded MNPs-
Fe3O4 fail to further suppress the growth of K562-n tumor 
cells. The advantages of nanoparticles over solution appear 
to be augmented by the increases in P-gp levels of the treated 
cells. This phenomenon is consistent with recent studies of 
polymer-lipid hybrid nanoparticle systems and Pluronic 
block copolymers.45,48 However, these mechanisms are not 
able to explain the remarkable selectivity of DNR-loaded 
MNPs-Fe3O4 complexes with respect to MDR cells. Since 
MNPs-Fe3O4 may not completely inhibit the P-gp function, 
DNR-loaded MNPs-Fe3O4 complexes are able to enhance 
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the DNR accumulation in P-gp negative cells at the same 
time as the MDR counterpart. It has been demonstrated 
that DNR–nanoparticle conjugates are transported via a 
different mechanism than the free drug. The conjugate is 
most likely to be transported in the cells via endocytosis, 
which represents a P-gp-independent pathway, whereas the 
free drug is transported via membrane diffusion, a pathway 
affected by efflux pumps.49 It also has been reported that 
endocytosis, secretion, and some other processes related to 
phase transitions in the plasma membrane are more active in 
MDR cells than in sensitive ones due to the higher membrane 
fluidity of the former.50 This suggests that the increase in 
the drug uptake observed in MDR cells in the presence of 
MNPs-Fe3O4 was conditioned by the higher flexibility of 
their membranes. P-gp is normally expressed in the transport 
epithelium of the liver, kidney, and gastrointestinal tract, 
at pharmacological barrier sites, in adult stem cells, and in 
assorted cells of the immune system.51,52 A wide variety of 
substrates are translocated by P-gp transporters, ranging from 
chemotherapeutic drugs to naturally occurring biological 
compounds. It is becoming increasingly evident that P-gp 
has a pivotal role in host detoxification and protection of the 
body against xenobiotics. We wonder if the abrogation of 
P-gp by tetraheptylammonium-capped MNPs-Fe3O4 would 
result in systemic toxicity. It has been reported that mdr-1a/1b 
double knockout mice are viable and fertile and are almost 
indistinguishable from their wild-type littermates, which 
suggests that pharmacological modulation of human P-gp 
could represent a safe and effective strategy to thwart MDR 
cancers.53 Our histological data show that the application of 
MNPs-Fe3O4 was well tolerated by nude mice.
In conclusion, our results support the proposition 
that MNPs-Fe3O4 offers an attractive means of delivering 
DNR into MDR tumor cells and enhances apoptosis in 
the MDR cells without reducing P-gp protein in the cell 
membrane. DNR-loaded MNPs-Fe3O4 complex is insensi-
tive to P-gp-mediated drug efflux and is more effective 
than free DNR in MDR cells. In any case, the DNR-
loaded MNPs-Fe3O4 complex may target the Achilles’ 
heel of MDR cells.
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